Aion Therapeutic Names James W.G. Thompson, Ph.D. as President
Toronto, Ontario--(Newsfile Corp. - October 21, 2020) - Aion Therapeutic Inc. (CSE: AION) ("Aion Therapeutic" or the "Company") is pleased to announce that the Company has named James W.G. Thompson, Ph.D. as its new president.Dr. Thompson is an accomplished neuroscientist and healthcare technology entrepreneur with over 20 years industry experience. Most recently he co-founded Evoke Neuroscience, Inc., a healthcare technology company founded in 2009 and focused on aiding diagnosis and therapy...
2020-10-21 9:15 AM EDT
Aion Therapeutic Announces Closing of Non-Brokered Private Placement
Toronto, Ontario--(Newsfile Corp. - September 18, 2020) - Aion Therapeutic Inc. (CSE: AION) ("Aion Therapeutic" or the "Company") is pleased to announce the closing of a non-brokered private placement through the issuance of 9,090,907 units ("Units") at a price of $0.055 per Unit for gross proceeds of approximately $500,000 (the "Offering"). The proceeds of the Offering will be used for general working capital purposes.Each Unit is comprised of one common share ("Common Share") of the Company...
2020-09-18 5:15 PM EDT
Aion Therapeutic, Inc. Announces the Appointment of Dr. Herbert Fritsche, Former Professor of Laboratory Medicine and Chief of the Clinical Chemistry Section at the University of Texas, MD Anderson Cancer Center in Houston, Texas as Chief Science Officer
Toronto, Ontario--(Newsfile Corp. - September 10, 2020) - Dr. Fritsche is a world-renowned Clinical Chemist and former Professor of Laboratory Medicine and Chief of the Clinical Chemistry Section at The University of Texas, MD Anderson Cancer Center in Houston, Texas for 41 years.He has published over 200 peer-reviewed scientific papers, invited articles and book chapters, and participated in the validation and FDA clearance process for most every commercial serum cancer marker currently in...
2020-09-10 9:00 AM EDT
Aion Therapeutic Files Five Patents with the United States Patent and Trademark Office
Toronto, Ontario--(Newsfile Corp. - September 3, 2020) - Aion Therapeutic Inc. (CSE: AION) ("Aion Therapeutic" or the "Company") is pleased to announce that the Company has filed five patent applications with the United States Patent and Trademark Office (USPTO) pertaining to new treatments combining healing compounds in medical cannabis with healing compounds from mushrooms (edible and psychedelic), and other natural plants known for their medicinal properties. These patent applications have...
2020-09-03 9:00 AM EDT
Aion Therapeutic's Dr. Stephen D. Barnhill to Present at Microdose "Psychedelic Capital Series" on September 3, 2020
Toronto, Ontario--(Newsfile Corp. - August 31, 2020) - Aion Therapeutic Inc. (CSE: AION) ("Aion" or the "Company") is pleased to announce that Dr. Stephen D. Barnhill, Executive Chair of the Board, will present live during the Microdose "Psychedelic Capital Series" on Thursday, September 3, 2020 at 1:15 P.M. Eastern Time.The Psychedelic Capital Series is an investor conference series diving deep into psychedelic medicine investment. Each month, Microdose presents a curated group of CEOs,...
2020-08-31 5:16 PM EDT
Osoyoos Announces Name Change to "Aion Therapeutic Inc."
Toronto, Ontario--(Newsfile Corp. - August 27, 2020) - Osoyoos Cannabis Inc. (CSE: OSO) ("Osoyoos" or the "Company") is pleased to announce that it will be changing its name to "Aion Therapeutic Inc." The Company's new stock symbol on the Canadian Securities Exchange will be "AION", and the name change will be effective on or about August 28, 2020. The Company expects there to be no impact or delays in trading."We are pleased to see our name and ticker symbol change...
2020-08-27 9:00 AM EDT
Osoyoos Provides Board Update; Approves Name Change
Toronto, Ontario--(Newsfile Corp. - August 19, 2020) - Osoyoos Cannabis Inc. (CSE: OSO) ("Osoyoos" or the "Company") is pleased to provide a Board of Directors ("Board of Directors" or the "Board") update following the recent election of the Company's new Board of Directors which includes the appointment of a new Executive Chair, Executive Vice Chair, Lead Independent Director, composition of all Board committees and Board approval of a corporate name change to Aion Therapeutic Inc.New Board...
2020-08-19 9:00 AM EDT
Osoyoos Retains Integrity Media for Investor Relations and Corporate Communications
Toronto, Ontario--(Newsfile Corp. - August 12, 2020) - Osoyoos Cannabis Inc. (CSE: OSO) ("Osoyoos" or the "Company") is pleased to announce that the Company has retained Integrity Media Inc. ("Integrity Media") to manage the Company's Investor Relations and Corporate Communications.Integrity Media has over two decades working in public markets and is highly experienced with cannabis and psychedelic-based public companies in the U.S., Canada, the Caribbean and South America. Integrity Media is...
2020-08-12 8:00 AM EDT
Osoyoos Announces Results of Annual and Special Meeting
Toronto, Ontario--(Newsfile Corp. - August 10, 2020) - Osoyoos Cannabis Inc. (CSE: OSO) ("Osoyoos" or the "Company") is pleased to announce the results from the Company's annual and special meeting of shareholders held on Friday, August 7, 2020 (the "Meeting").Shareholders holding a total of 34,335,039 common shares of the Company were represented in person or by proxy at the Meeting, representing 46.29% of the votes attached to all outstanding common shares of the Company as at the record...
2020-08-10 9:00 AM EDT
Osoyoos Closes Non-Brokered Private Placement
Toronto, Ontario--(Newsfile Corp. - August 4, 2020) - Osoyoos Cannabis Inc. (CSE: OSO) ("Osoyoos" or the "Company") is pleased to announce that the Company has closed its previously announced non-brokered private placement (the "Private Placement") of up to 20,000,000 units of the Company (the "Units"), at a price of $0.05 per Unit, for gross proceeds of up to $1,000,000.Each Unit will consist of one common share of the Company (a "Common Share") and one-half of one common share purchase...
2020-08-04 9:00 AM EDT
Osoyoos Closes Tranche of Non-Brokered Private Placement
Toronto, Ontario--(Newsfile Corp. - July 20, 2020) - Osoyoos Cannabis Inc. (CSE: OSO) ("Osoyoos" or the "Company") announced today that the Company has closed a second tranche of its previously announced non-brokered private placement (the "Private Placement") of up to 20,000,000 units of the Company (the "Units"), at a price of $0.05 per Unit, for gross proceeds of up to $1,000,000.Each Unit will consist of one common share of the Company (a "Common Share") and one-half of one common share...
2020-07-20 5:00 PM EDT
Osoyoos Provides Corporate Update on AI Pharma Acquisition
Toronto, Ontario--(Newsfile Corp. - July 8, 2020) - Osoyoos Cannabis Inc. (CSE: OSO) ("Osoyoos" or the "Company") today provided a corporate update on its previously announced acquisition of 1196691 B.C. Ltd. d/b/a "PCAI Pharma" ("PCAI") and its wholly-owned subsidiary AI Pharmaceuticals Jamaica Limited ("AI Pharma").About PCAIPCAI is a Toronto-based pharmaceutical company with an ongoing mission, through AI Pharma, to build a global enterprise with a strong foundation of science, research,...
2020-07-08 9:15 AM EDT
Osoyoos Announces Closing of Acquisition of AI Pharmaceuticals Jamaica Limited
Toronto, Ontario--(Newsfile Corp. - June 30, 2020) - Osoyoos Cannabis Inc. (CSE: OSO) ("Osoyoos" or the "Company") announced today that it completed its previously announced acquisition of AI Pharmaceuticals Jamaica Limited ("AI Pharma"), a company engaged in the research and development of cannabis (cannabinoids) and mushrooms (psilocin) based pharmaceutical, nutraceutical and cosmeceutical formulations and related intellectual property (the "Acquisition"). In connection with the...
2020-06-30 9:15 AM EDT
Osoyoos Announces Agreement to Acquire AI Pharmaceuticals Jamaica Limited
Toronto, Ontario--(Newsfile Corp. - June 26, 2020) - Osoyoos Cannabis Inc. (CSE: OSO) ("Osoyoos" or the "Company") announced today that it has agreed to acquire 100% of the shares (the "Acquisition") of 1196691 B.C. Ltd. d/b/a "PCAI Pharma" (the "Parent") the parent company that holds 100% of the shares of AI Pharmaceuticals Jamaica Limited ("AI Pharma"). AI Pharma is engaged in the research and development of cannabis (cannabinoids) and mushrooms (psilocin) based pharmaceutical,...
2020-06-26 8:00 PM EDT
Osoyoos Announces Non-Brokered Private Placement
Toronto, Ontario--(Newsfile Corp. - June 16, 2020) - Osoyoos Cannabis Inc. (CSE: OSO) ("Osoyoos" or the "Company") announced today that it proposes to complete a non-brokered private placement (the "Private Placement") of up to 20,000,000 units of the Company (the "Units"), at a price of $0.05 per Unit, for gross proceeds of up to $1,000,000. Each Unit will consist of one common share of the Company (a "Common Share") and one-half of one common share purchase warrant of the Company...
2020-06-16 4:30 PM EDT
Osoyoos Provides Update on Annual and Special Meeting
Toronto, Ontario--(Newsfile Corp. - June 4, 2020) - Osoyoos Cannabis Inc. (CSE: OSO) ("Osoyoos" or the "Company") announced today that the Company has rescheduled its next annual and special meeting of shareholders (the "Annual Meeting") to be held on August 7, 2020. Management had initially scheduled its Annual Meeting to be held on July 20, 2020 in anticipation that it would be able to complete and include the Company's audited annual financial statements for year ended April 30, 2020 (the...
2020-06-04 5:20 PM EDT
Osoyoos' Extraction Systems Now Commissioned and Approved
Toronto, Ontario--(Newsfile Corp. - May 26, 2020) - Osoyoos Cannabis Inc. (CSE: OSO) ("Osoyoos" or the "Company") is pleased to announced that both of the Company's Vitalis Q-180 Series extraction systems (the "Extraction Systems") have been commissioned for operation and all requisite approvals from the federal and provincial regulators have been received for both processing and sale of materials.As previously disclosed in the Company's release, dated April 21, 2020, the Extraction Systems...
2020-05-26 9:00 AM EDT
Osoyoos Enters into Equipment Lease and Joint-Venture Agreement; Provides Corporate Update
Toronto, Ontario--(Newsfile Corp. - April 21, 2020) - Osoyoos Cannabis Inc. (CSE: OSO) ("Osoyoos" or the "Company") announced today that the Company has entered into an equipment lease (the "Equipment Lease") and a joint-venture agreement (the "JV Agreement") with 2623942 Ontario Limited (the "Licensed Producer"). Furthermore, the Company is also pleased to provide a corporate update regarding its next annual and special meeting of shareholders and results of management's operational...
2020-04-21 4:30 PM EDT
Osoyoos Provides Corporate Update; Announces Board and Management Changes
Toronto, Ontario--(Newsfile Corp. - January 20, 2020) - Osoyoos Cannabis Inc. (CSE: OSO) ("Osoyoos" or the "Company") announced today that the Company's board of directors has accepted the resignation of Ernie Eves as a director of the Company and has appointed Graham Simmonds, Tyler Devenyi and Larry Horwitz to serve as directors of the Company, all effective January 16, 2020. The Company's board currently consists of six directors. Osoyoos also reports that its board of directors has...
2020-01-20 4:00 PM EST
Osoyoos Announces Debt Settlement
Toronto, Ontario--(Newsfile Corp. - September 23, 2019) - Osoyoos Cannabis Inc. (CSE: OSO) ("Osoyoos" or the "Company") announces that it has entered into a debt settlement agreement with an arm's length creditor. The agreement reduces the Company's liabilities by $750,000 and improves the Company's financial position with respect to both continued execution of its business plan and evaluation of potential corporate transactions.In final settlement of the debt of $1,000,000, Osoyoos has...
2019-09-23 7:30 AM EDT